Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ending Subclinical Heart Failure Using an Aldosterone and Natriuretic Peptide Targeted Treatment in HIV--The ENCHANTMENT HIV Study

NCT04153136 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT04153136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04153136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ending Subclinical Heart Failure Using an Aldosterone and Natriuretic Peptide Targeted Treatment in HIV--The ENCHANTMENT HIV Study
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Completed
Start date
September 11, 2020
Completion date
July 9, 2025
Enrollment
39 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with preserved ejection fraction, hiv/aids